Integra LifeSciences Reports Third Quarter 2025 Financial Results

• Third quarter revenues of $402.1 million increased 5.6% on a reported basis and 5.0% on an organic basis compared to the prior year.
• Third quarter GAAP earnings per diluted share of $(0.07), compared to $(0.14) in the prior year.
• Adjusted earnings per diluted share of $0.54, compared to $0.41 in the prior year.
• Relaunch of PriMatrix® and Durepair® ahead of schedule, through dual sourcing supply strategy.
• Appointed Dr. Raymond Turner, a board-certified neurosurgeon, fellowship-trained in endovascular neurosurgery, as chief medical officer.
• Revising 2025 guidance to reflect third quarter revenue and updated assumptions for the fourth quarter.

“In the third quarter, we continued to see healthy demand across our portfolio. While revenue was impacted by two supply interruptions, we delivered strong profitability and cash flow through disciplined cost management and operational efficiencies.” said Mojdeh Poul, president and chief executive officer. “We are making progress in implementing our comprehensive plan to systematically strengthen the entirety of our supply chain and quality management system, and we remain confident in our strategy to improve overall performance and drive the Company’s transformation.”

Click here for the full press release.